Aprepitant
- Generic Name
- Aprepitant
- Brand Names
- Aponvie, Cinvanti, Emend
- Drug Type
- Small Molecule
- Chemical Formula
- C23H21F7N4O3
- CAS Number
- 170729-80-3
- Unique Ingredient Identifier
- 1NF15YR6UY
- Background
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substan...
- Indication
For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Post Operative Nausea and Vomiting (PONV), Acute delayed Nausea caused by highly emetogenic cancer chemotherapy
- Associated Therapies
- -
Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant
- Conditions
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Kyungpook National University Hospital
- Target Recruit Count
- 88
- Registration Number
- NCT02597907
A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2016-12-30
- Lead Sponsor
- Jun Zhu
- Target Recruit Count
- 130
- Registration Number
- NCT02576327
Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy
- Conditions
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 19
- Registration Number
- NCT02550119
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries
- Conditions
- Interventions
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2016-03-24
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 150
- Registration Number
- NCT02525848
- Locations
- 🇪🇬
Hala saad Abdel-Ghaffar, Assiut, Assiut governorate, Egypt
Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2017-03-30
- Target Recruit Count
- 120
- Registration Number
- NCT02484911
- Locations
- 🇨🇳
First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2015-05-15
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 80
- Registration Number
- NCT02445872
- Locations
- 🇨🇳
The first affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China
Palonosetron Associated to Aprepitant in Prophylaxis of PONV
- Conditions
- Interventions
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Instituto do Cancer do Estado de São Paulo
- Target Recruit Count
- 90
- Registration Number
- NCT02431286
- Locations
- 🇧🇷
Angela Maria Sousa, Sao Paulo, São Paulo, Brazil
A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2015-02-18
- Last Posted Date
- 2020-09-01
- Lead Sponsor
- Shiga University
- Target Recruit Count
- 10
- Registration Number
- NCT02364804
- Locations
- 🇯🇵
Shiga University of Medical Science Hospital, Otsu, Shiga, Japan
Neurokinin Receptor Antagonist Associated to Ondansetron in PONV
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Instituto do Cancer do Estado de São Paulo
- Target Recruit Count
- 90
- Registration Number
- NCT02357693
- Locations
- 🇧🇷
Angela Maria Sousa, Sao Paulo, São Paulo, Brazil
Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 85
- Registration Number
- NCT02347878
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.